Andrew Robb's most recent trade in Mannatech Inc was a trade of 4,790 Common stock, par value $0.0001 done at an average price of $8.4 . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 8.35 per share. | 02 Jan 2026 | 4,790 | 26,233 (1%) | 0% | 8.4 | 39,997 | Common stock, par value $0.0001 |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 840,000 | 1,025,000 (3%) | 2% | 0 | Common Stock | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.45 per share. | 17 Dec 2025 | 367,497 | 657,503 (2%) | 1% | 39.5 | 14,497,757 | Common Stock |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 245,000 | 245,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 185,000 | 185,000 (0%) | 0% | 0 | Common Stock | |
| 1stdibs.com Inc | Andrew G. Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2025 | 31,380 | 0 | - | - | Restricted Stock Units | |
| 1stdibs.com Inc | Andrew G. Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2025 | 31,380 | 74,618 | - | - | Common Stock | |
| Tamboran Resources Corp | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 5,002 | 9,507 | - | 0 | Common Stock | |
| International Paper | David Andrew Robbie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2025 | 3,953 | 8,864 (0%) | 0% | 0 | Common Stock | |
| International Paper | David Andrew Robbie | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.91 per share. | 12 May 2025 | 317 | 8,547 (0%) | 0% | 47.9 | 15,187 | Common Stock |
| 1stdibs.com Inc | Andrew G. Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 40,926 | 40,926 | - | - | Restricted Stock Units | |
| International Paper | David Andrew Robbie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 1,065 | 4,920 (0%) | 0% | 0 | Common Stock | |
| Tamboran Resources Corp | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 2,505 | 4,505 | - | 0 | Common Stock | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 915,000 | 915,000 | - | - | Stock Option (Right to Buy) | |
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 14.89 per share. | 02 Jan 2025 | 2,686 | 21,443 (0%) | 0% | 14.9 | 39,995 | Common Stock Par Value $0.0001 Per Share |
| Tamboran Resources Corp | Andrew Robb | Director | Purchase of securities on an exchange or from another person at price $ 24.00 per share. | 28 Jun 2024 | 2,000 | 2,000 | - | 24 | 48,000 | Common Stock |
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 5,000 | 15,000 | - | - | Right to Purchase Common Stock | |
| 1stdibs.com Inc | Andrew Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 28,533 | 0 | - | - | Restricted Stock Units | |
| 1stdibs.com Inc | Andrew Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 28,533 | 43,238 | - | - | Common Stock | |
| 1stdibs.com Inc | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2024 | 31,380 | 31,380 | - | - | Restricted Stock Units | |
| 1stdibs.com Inc | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2024 | 31,380 | 31,380 | - | - | Restricted Stock Units | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,100,000 | 1,100,000 | - | - | Stock Option (Right to Buy) | |
| Mannatech Inc | Andrew Robbins Kevin | Director | Grant, award, or other acquisition of securities at price $ 8.11 per share. | 02 Jan 2024 | 4,932 | 18,757 (0%) | 0% | 8.1 | 39,999 | Common Stock Par Value $0.0001 Per Share |
| Harpoon Therapeutics Inc | Andrews R. Robbins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 23,000 | 23,000 | - | - | Director Stock Option (Right to Buy) | |
| 1stdibs.com Inc | Andrew Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 14,705 | 14,705 | - | - | Common Stock | |
| 1stdibs.com Inc | Andrew Robb | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 14,705 | 0 | - | - | Restricted Stock Units | |
| 1stdibs.com Inc | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 28,533 | 28,533 | - | - | Restricted Stock Units | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 03 Jan 2023 | 2,294 | 13,825 (0%) | 0% | 17.4 | 39,984 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 08 Dec 2022 | 1,500 | 11,531 (0%) | 0% | 22 | 33,000 | Common Stock Par Value $0.0001 Per Share |
| Harpoon Therapeutics Inc | Andrews R. Robbins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 10,167 | 10,167 | - | - | Director Stock Option (Right to Buy) | |
| 1stdibs.com Inc | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 14,705 | 14,705 | - | - | Restricted Stock Units | |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 36.57 per share. | 28 Mar 2022 | 1,100 | 13,031 (0%) | 0% | 36.6 | 40,227 | Common Stock Par Value $0.0001 Per Share |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 690,000 | 690,000 | - | - | Stock Option (Right to Buy) | |
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 39.49 per share. | 03 Jan 2022 | 1,012 | 14,131 (0%) | 0% | 39.5 | 39,964 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 5,000 | 0 | - | - | Right to Purchase Common Stock | |
| Mannatech Inc | Kevin Andrew Robbins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.28 per share. | 26 Aug 2021 | 5,000 | 13,119 (0%) | 0% | 17.3 | 86,400 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 32.99 per share. | 23 Aug 2021 | 1,500 | 8,119 (0%) | 0% | 33.0 | 49,485 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 32.24 per share. | 20 Aug 2021 | 1,000 | 9,619 (0%) | 0% | 32.2 | 32,240 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 30.83 per share. | 17 Aug 2021 | 2,000 | 11,130 (0%) | 0% | 30.8 | 61,660 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 17 Aug 2021 | 11 | 11,119 (0%) | 0% | 32 | 352 | Common Stock Par Value $0.0001 Per Share |
| Mannatech Inc | Kevin Andrew Robbins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 5,000 | 15,000 | - | - | Right to Purchase Common Stock | |
| 1stdibs.com Inc | Andrew Robb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 17,667 | 17,667 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 315,200 | 315,200 | - | - | Stock Option (Right to Buy) |